![](https://monteverdelaw.com/wp-content/uploads/case-logo/theseus-pharmaceuticals-inc.jpg)
Theseus Pharmaceuticals, Inc. (Nasdaq: THRX), relating to its proposed sale to Concentra Biosciences, LLC. Under the terms of the agreement, THRX shareholders are expected to receive between $3.90 and $4.05 in cash per share they own
Theseus Pharmaceuticals, Inc. (Nasdaq: THRX), relating to its proposed sale to Concentra Biosciences, LLC. Under the terms of the agreement, THRX shareholders are expected to receive between $3.90 and $4.05 in cash per share they own